Bone Loss
Bone drugs may not protect osteoporotic women from breast cancer
August 25, 2014Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study.
Guidance to prevent fractures in cancer-associated bone disease
November 19, 2013The epidemiology and pathophysiology of cancer-associated bone disease was reviewed in a new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group.
Calcium/vitamin D don't stop bone loss in breast cancer
September 24, 2013A review of calcium and vitamin D supplementation trials revealed that current recommended doses are inadequate to prevent bone mineral density loss in women undergoing breast cancer therapy.
A roundup of FDA news from June 2013
July 05, 2013FDA-related news items of relevance from the month of June, 2013.
Burden of giant-cell tumor of the bone reduced by denosumab
September 27, 2012When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
Calcium and vitamin D may hurt, not help, in prostate cancer
August 28, 2012Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.
Denosumab Better for Breast Cancer With Bone Metastases
August 16, 2012Denosumab better prevents skeletal complications, ups health-related QoL versus zoledronic acid.
Gum disease may affect HPV status of head-and-neck tumors
July 12, 2012A history of periodontitis may be associated with an increased risk of HPV-positive tumors in persons with head and neck squamous cell carcinoma.
BMD loss occurs early in androgen deprivation therapy
April 12, 2012Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer.
Bone loss risk highlighted
January 26, 2010The risk of bone loss resulting from breast and prostate cancer treatment has been highlighted by researchers in Canada.
Sign Up for Free e-newsletters
ONA Articles
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- Handling Chemotherapy Premedications
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |